177 related articles for article (PubMed ID: 17487487)
1. Cytokine-induced killer cells targeted by the novel bispecific antibody CD19xCD5 (HD37xT5.16) efficiently lyse B-lymphoma cells.
Tita-Nwa F; Moldenhauer G; Herbst M; Kleist C; Ho AD; Kornacker M
Cancer Immunol Immunother; 2007 Dec; 56(12):1911-20. PubMed ID: 17487487
[TBL] [Abstract][Full Text] [Related]
2. Targeting of natural killer-like T immunologic effector cells against leukemia and lymphoma cells by reverse antibody-dependent cellular cytotoxicity.
Lefterova P; Märten A; Buttgereit P; Weineck S; Scheffold C; Huhn D; Schmidt-Wolf IG
J Immunother; 2000; 23(3):304-10. PubMed ID: 10838659
[TBL] [Abstract][Full Text] [Related]
3. Performance of CD3xCD19 bispecific monoclonal antibodies in B cell malignancy.
Haagen IA
Leuk Lymphoma; 1995 Nov; 19(5-6):381-93. PubMed ID: 8590837
[TBL] [Abstract][Full Text] [Related]
4. The apoptotic and proliferative fate of cytokine-induced killer cells after redirection to tumor cells with bispecific Ab.
Kornacker M; Verneris M; Kornacker B; Ganten T; Scheffold C; Negrin R
Cytotherapy; 2006; 8(1):13-23. PubMed ID: 16627341
[TBL] [Abstract][Full Text] [Related]
5. A recombinant bispecific single-chain antibody, CD19 x CD3, induces rapid and high lymphoma-directed cytotoxicity by unstimulated T lymphocytes.
Löffler A; Kufer P; Lutterbüse R; Zettl F; Daniel PT; Schwenkenbecher JM; Riethmüller G; Dörken B; Bargou RC
Blood; 2000 Mar; 95(6):2098-103. PubMed ID: 10706880
[TBL] [Abstract][Full Text] [Related]
6. A bispecific single-chain antibody directed against EpCAM/CD3 in combination with the cytokines interferon alpha and interleukin-2 efficiently retargets T and CD3+CD56+ natural-killer-like T lymphocytes to EpCAM-expressing tumor cells.
Flieger D; Kufer P; Beier I; Sauerbruch T; Schmidt-Wolf IG
Cancer Immunol Immunother; 2000 Oct; 49(8):441-8. PubMed ID: 11043851
[TBL] [Abstract][Full Text] [Related]
7. In vivo studies using bispecific antibodies (anti-CD3 x anti-idiotype) and CD28-induced costimulation in the BCL1 lymphoma.
Demanet C; Brissinck J; De Jonge J; Thielemans K
J Hematother; 1995 Oct; 4(5):363-8. PubMed ID: 8581370
[TBL] [Abstract][Full Text] [Related]
8. Activation of T cell cytotoxicity against autologous common acute lymphoblastic leukemia (cALL) blasts by CD3xCD19 bispecific antibody.
Csóka M; Strauss G; Debatin KM; Moldenhauer G
Leukemia; 1996 Nov; 10(11):1765-72. PubMed ID: 8892680
[TBL] [Abstract][Full Text] [Related]
9. The efficacy of CD3 x CD19 bispecific monoclonal antibody (BsAb) in a clonogenic assay: the effect of repeated addition of BsAb and interleukin-2.
Haagen IA; Geerars AJ; de Lau WB; Bast BJ; de Gast BC
Blood; 1995 Jun; 85(11):3208-12. PubMed ID: 7538821
[TBL] [Abstract][Full Text] [Related]
10. Potent ex vivo armed T cells using recombinant bispecific antibodies for adoptive immunotherapy with reduced cytokine release.
Park JA; Santich BH; Xu H; Lum LG; Cheung NV
J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 33986124
[TBL] [Abstract][Full Text] [Related]
11. Clinical experience with CD3 x CD19 bispecific antibodies in patients with B cell malignancies.
De Gast GC; Van Houten AA; Haagen IA; Klein S; De Weger RA; Van Dijk A; Phillips J; Clark M; Bast BJ
J Hematother; 1995 Oct; 4(5):433-7. PubMed ID: 8581381
[TBL] [Abstract][Full Text] [Related]
12. Killing of human leukaemia/lymphoma B cells by activated cytotoxic T lymphocytes in the presence of a bispecific monoclonal antibody (alpha CD3/alpha CD19).
Haagen IA; van de Griend R; Clark M; Geerars A; Bast B; de Gast B
Clin Exp Immunol; 1992 Dec; 90(3):368-75. PubMed ID: 1281055
[TBL] [Abstract][Full Text] [Related]
13. Locoregional treatment of low-grade B-cell lymphoma with CD3xCD19 bispecific antibodies and CD28 costimulation. II. Assessment of cellular immune responses.
Manzke O; Tesch H; Lorenzen J; Diehl V; Bohlen H
Int J Cancer; 2001 Feb; 91(4):516-22. PubMed ID: 11251975
[TBL] [Abstract][Full Text] [Related]
14. BL-01, an Fc-bearing, tetravalent CD20 × CD5 bispecific antibody, redirects multiple immune cells to kill tumors in vitro and in vivo.
Interdonato A; Choblet S; Sana M; Valgardsdottir R; Cribioli S; Alzani R; Roth M; Duonor-Cerutti M; Golay J
Cytotherapy; 2022 Feb; 24(2):161-171. PubMed ID: 34538717
[TBL] [Abstract][Full Text] [Related]
15. Release of cytokines and soluble cell surface molecules by PBMC after activation with the bispecific antibody CD3 x CD19.
Klein SC; Boer LH; de Weger RA; de Gast GC; Bast EJ
Scand J Immunol; 1997 Nov; 46(5):452-8. PubMed ID: 9393627
[TBL] [Abstract][Full Text] [Related]
16. Cord blood-derived cytokine-induced killer cells combined with blinatumomab as a therapeutic strategy for CD19
Golay J; Martinelli S; Alzani R; Cribioli S; Albanese C; Gotti E; Pasini B; Mazzanti B; Saccardi R; Rambaldi A; Introna M
Cytotherapy; 2018 Aug; 20(8):1077-1088. PubMed ID: 30093325
[TBL] [Abstract][Full Text] [Related]
17. Immunotherapy of B-cell non-Hodgkin lymphoma by targeting the chemokine receptor CXCR5 in a preclinical mouse model.
Panjideh H; Müller G; Koch M; Wilde F; Scheu S; Moldenhauer G; Lipp M
Int J Cancer; 2014 Dec; 135(11):2623-32. PubMed ID: 24729415
[TBL] [Abstract][Full Text] [Related]
18. A fully human CD19/CD3 bi-specific antibody triggers potent and specific cytotoxicity by unstimulated T lymphocytes against non-Hodgkin's lymphoma.
Zhou Y; Gou LT; Mu B; Liao WC; He J; Ma C; Yao YQ; Yang JL
Biotechnol Lett; 2012 Jul; 34(7):1183-91. PubMed ID: 22421972
[TBL] [Abstract][Full Text] [Related]
19. Cytokine-induced killer (CIK) cells bound with anti-CD3/anti-CD133 bispecific antibodies target CD133(high) cancer stem cells in vitro and in vivo.
Huang J; Li C; Wang Y; Lv H; Guo Y; Dai H; Wicha MS; Chang AE; Li Q
Clin Immunol; 2013 Oct; 149(1):156-68. PubMed ID: 23994769
[TBL] [Abstract][Full Text] [Related]
20. Bispecific antibody-mediated immunotherapy of the BCL1 lymphoma: increased efficacy with multiple injections and CD28-induced costimulation.
Demanet C; Brissinck J; De Jonge J; Thielemans K
Blood; 1996 May; 87(10):4390-8. PubMed ID: 8639800
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]